Form 4 · BMY
Bristol Myers Squibb director Phyllis R. Yale reports an award of about 561 deferred share units
Phyllis R. Yale, a Bristol Myers Squibb director, filed a Form 4 on Oct 2, 2026 at 4:26 PM ET reporting transactions on Sep 30, 2026.
The filing reports about 561 deferred share units in a grant or award (code A).
Reporting person
- Phyllis R. Yale, director (as filed: YALE PHYLLIS R)
Transactions as reported
| Date | Code | Security | Shares | Price | Acquired or disposed | Held after | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | A | Deferred Share Units (derivative) | 561 | $62.40 | Acquired | 45,980 | Direct |
Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.
Source
- Form 4 filed Oct 2, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Bristol Myers Squibb company file → · More Bristol Myers Squibb filings
Disclosures
- Editor holdings in BMY
- The editor holds no position in Bristol Myers Squibb (BMY). As of Oct 25, 2026.
- Last updated
- Oct 25, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold BMY.